Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.
about
Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a referenceO(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problemsMGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastomaIDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeA randomized trial of bevacizumab for newly diagnosed glioblastomaAssessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II studyEarly termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adultsPrecision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cellsComprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBMReview: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapiesAbsence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomidePhase II trial of 7 days on/7 days off temozolmide for recurrent high-grade gliomaSerum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various gradesPrognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.Formalin fixation in the '-omics' era: a primer for the surgeon-scientist.A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescenceImpact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastomaMGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of gliomaMGMT testing allows for personalised therapy in the temozolomide era.The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma.Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas.MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-statusAdvances in the management of glioblastoma: the role of temozolomide and MGMT testing.Standards of care for treatment of recurrent glioblastoma--are we there yet?Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.Extended survival of glioblastoma patients after chemoprotective HSC gene therapyIntratumoral Heterogeneity of the Epigenome.Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of GlioblastomaEnzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.High specificity of quantitative methylation-specific PCR analysis for MGMT promoter hypermethylation detection in gliomas.Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapyDose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.Association between response to primary treatments and MGMT status in glioblastoma.
P2860
Q21261312-79DD8DF2-DDAE-4141-BB19-5BE7728F6BDDQ26853112-09645D91-326B-4D90-89ED-F1829DB22B92Q27851529-EDA6FB4C-440D-498C-8A44-17C199DCCA46Q28731328-C9C4FA97-D0B4-4B52-BBB0-8BC7AD319209Q29617457-BD3C1109-854F-400D-BB74-4C2E1388AC0AQ30410163-730864AE-7134-401A-9D79-69ED3C5688C6Q30836702-3A4A71EF-9720-476A-9259-C056A1596E4EQ33403967-E6FF20AA-A7CD-4085-8B80-A8F741258F77Q33406808-204AEB54-9E0D-4286-BD63-E421EEA8A950Q33414998-370961C8-B9E4-44E1-94BC-3C54B0148AB1Q33499541-EC7BF681-845C-413A-B5B2-D6381FA25777Q33511367-ABBB6BE9-827D-437D-80E4-761ED81CA411Q33525767-0BF9289A-68FA-4E08-8EEF-AB42D7C4139EQ33797741-2E0AE1DB-0A5C-4F68-9571-9B004D06C7A0Q33925544-4781A5E7-4865-4F60-9453-9A114383260DQ34000287-4CD1068B-3E04-4F57-A830-CF8EA2180128Q34062033-5DB75161-A6CF-4D1C-AB29-60857D55D359Q34132740-A60FC40E-2B0A-4F3B-B299-E799F14A7FEAQ34168829-21447BA6-BC70-49C0-A895-CD1F8CB96220Q34263623-EFC6692F-277E-4B7D-ACA4-D99003A0F4FDQ34269566-74479665-EFA9-4059-9F3C-0D6704975BA9Q34478948-B61D258A-15B2-48BD-BC71-D56094673E62Q35085317-09D2C4A6-3D74-4431-8C59-9D421B02B9ABQ35724352-AE6FEDFE-C406-4718-BB1E-068F3057C284Q35803479-4CEFC4BF-599C-4EE4-BC06-8031F6D73219Q35827916-3B4A9BE4-BC2B-4888-9B54-504A7684B60EQ35992345-C1766E45-56DF-4219-B218-D03B75703E58Q36087220-7727B154-7AAA-4525-95C4-FE63552D9573Q36240860-7D4732BB-1A4D-4372-9BC2-09059A60E168Q36500074-A5D86B39-0B1E-4C92-8A7E-10162FA3E70AQ36500401-21EE3FF2-A754-4C63-ADBE-67354E1EA51BQ36523499-8D92F853-180B-4740-A46C-67F74FC42C45Q36834118-1EB5C0A7-5272-4921-9DF2-02FB6BB04013Q36854908-24D8082E-4C80-43B3-ACC2-DC1EB949CCC4Q36887663-CBCA69A5-5A78-4C67-8FB1-5C07BD8BBC2DQ37187715-B92F4FAD-7F0B-4102-BF3C-D8166701CE5FQ37208268-192E4871-7911-4233-973F-01960B66B82AQ37269674-0CE2FD40-7C7D-4137-8BEA-11A64A2E9392Q37278379-59C60728-DB5B-459A-8509-EEA9CAFFDD89Q37316991-D5A0C8FE-23D3-4111-8BAF-ACDF17269A9D
P2860
Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Validation of real-time methyl ...... romoter methylation in glioma.
@ast
Validation of real-time methyl ...... romoter methylation in glioma.
@en
type
label
Validation of real-time methyl ...... romoter methylation in glioma.
@ast
Validation of real-time methyl ...... romoter methylation in glioma.
@en
prefLabel
Validation of real-time methyl ...... romoter methylation in glioma.
@ast
Validation of real-time methyl ...... romoter methylation in glioma.
@en
P2093
P2860
P1476
Validation of real-time methyl ...... promoter methylation in glioma
@en
P2093
Annie-Claire Diserens
Bruno Flamion
Eugenia Migliavacca
Fabrice Moreau
Ilse Vlassenbroeck
Isabelle Renard
Ivano Di Stefano
James DiGuiseppi
Josef Straub
Katja Bierau
P2860
P304
P356
10.2353/JMOLDX.2008.070169
P577
2008-06-13T00:00:00Z